Top-News

Nektar Therapeutics Aktie News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Pharmazeutika Land:  USA
56,90 $
-0,79 $
-1,37%
48,867 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
9,08 Mrd. €
Streubesitz
31,57%
KGV
-
Index-Zuordnung
-

Nektar Therapeutics News

05.12.25 - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
30.11.25 - Der Aktionär
Nektar Therapeutics: "Marktpotenzial in Milliardenhöhe" – CBO im Exklusiv‑Interview (Teil 2)
30.11.25 - Der Aktionär
Nektar Therapeutics: "Unser Wirkmechanismus ist breit gefächert"– CBO im Exklusiv‑Interview (Teil 1)
08.11.25 - PR Newswire
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
New Data from REZOLVE-​AD Study of Rezpegaldesleukin Presented in Late-​Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting PR Newswire
06.11.25 - PR Newswire
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
Nektar Therapeutics Reports Third Quarter 2025 Financial Results PR Newswire
30.10.25 - PR Newswire
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London PR Newswire
28.10.25 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets PR Newswire
22.10.25 - PR Newswire
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Data from REZOLVE-​AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-​Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting PR Newswire
18.09.25 - PR Newswire
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Nektar Presents New Data from REZOLVE-​AD Phase 2b Study for Rezpegaldesleukin in Late-​Breaker Oral Presentation at EADV 2025 PR Newswire
09.09.25 - PR Newswire
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
Nektar Announces REZOLVE-​AD Phase 2b Results for Rezpegaldesleukin Selected for Late-​Breaker Oral Presentation at EADV 2025 PR Newswire
03.09.25 - PR Newswire
Nektar Therapeutics to Participate in Two Investor Conferences in September
Nektar Therapeutics to Participate in Two Investor Conferences in September PR Newswire
14.08.25 - PR Newswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment PR Newswire
07.08.25 - PR Newswire
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
Nektar Therapeutics Reports Second Quarter 2025 Financial Results PR Newswire
31.07.25 - PR Newswire
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets PR Newswire
29.07.25 - PR Newswire
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-​to-Very Severe Alopecia Areata PR Newswire
02.07.25 - PR Newswire
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
01.07.25 - PR Newswire
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Nektar Therapeutics Announces Pricing of $100 Million Public Offering PR Newswire
30.06.25 - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering
Nektar Therapeutics Announces Proposed Public Offering PR Newswire
24.06.25 - PR Newswire
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-​to-Severe Atopic Dermatitis PR Newswire
23.06.25 - PR Newswire
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »